FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.

Main|Search|PHGKB

Publication
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Odogwu Lauretta et al. The oncologist 2018 Feb Similar articles in PubMed
Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. Hughes Kevin S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jul JCO2017741744 Similar articles in PubMed
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Caudle Kelly E et al. Genetics in medicine : official journal of the American College of Medical Genetics 2016 Jul Similar articles in PubMed
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. Hall Jennifer L et al. Circulation. Cardiovascular genetics 2016 Mar Similar articles in PubMed
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Similar articles in PubMed
Electronic family health history records draw attention: proposed federal regulation and new tool emphasize digital conversion. Similar articles in PubMed